Clinical Trial: A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07293351) titled 'A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)' on Dec. 17.

Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)

Study Start Date: March 26, 2026

Study Type: INTERVENTIONAL

Condition: Advanced Renal Cell Carcinoma (RCC)

Intervention: DRUG: Pumitamig

Specified dose on specified days

DRUG: Ipilimumab

Specifi...